EA200800655A1 - Производные азабициклогексана - Google Patents

Производные азабициклогексана

Info

Publication number
EA200800655A1
EA200800655A1 EA200800655A EA200800655A EA200800655A1 EA 200800655 A1 EA200800655 A1 EA 200800655A1 EA 200800655 A EA200800655 A EA 200800655A EA 200800655 A EA200800655 A EA 200800655A EA 200800655 A1 EA200800655 A1 EA 200800655A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
azabiclogexane
derivatives
nervosa
hyperchondriasis
Prior art date
Application number
EA200800655A
Other languages
English (en)
Other versions
EA016084B1 (ru
Inventor
Дитер Хампрехт
Кристиан Хейдбредер
Серджо Мелотто
Фабрицио Микели
Тадатака Ямада
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200800655A1 publication Critical patent/EA200800655A1/ru
Publication of EA016084B1 publication Critical patent/EA016084B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Настоящее изобретение относится к новому применению соединения формулы (I) или его фармацевтически приемлемой соли или сольвата, в котором G выбирают из группы, включающей фенил, пиридил, бензотиазолил, индазолил; р означает целое число от 0 до 5; Rнезависимо выбирают из группы, включающей галоген, гидроксил, циано, Салкил, галогенСалкил, Салкокси, галогенСалкокси, Салканоил, или соответствует группе R; Rозначает водород или Салкил; Rозначает Салкил; Rозначает водород или фенильную группу, гетероциклическую группу, 5- или 6-членную гетероароматическую группу, 8- или 11-членную бициклическую группу, любая из которых может быть необязательно замещена 1, 2, 3 или 4 заместителями, выбираемыми из группы, включающей галоген, циано, Салкил, галогенСалкил, Cалкокси, Салканоил; Rозначает фрагмент, выбираемый из группы, включающей изоксазолил, -СН-N-пирролил, 1,1-диоксидо-2-изотиазолидинил, тиенил, тиазолил, пиридил, 2-пирролидинонил, причем такая группа необязательно замещена одним или двумя заместителями, выбираемыми из группы, включающей галоген, циано, Салкил, галогенСалкил, Салкокси, Салканоил; и когда Rозначает хлор и р равно 1, такой Rотсутствует в орто-положении относительно связи с остальной частью молекулы; и когда Rсоответствует R, р равно 1; для приготовления лекарственного средства для лечения соматоформного расстройства, такого как дисморфное расстройство или ипохондрия, нейрогенная булимия, нейрогенная анорексия, переедание, парафилия и непарафилическое половое влечение, хорея Сиденгама, кривошея, аутизм, двигательное расстройство, включая синдром Туретта; и преждевременной эякуляции
EA200800655A 2005-08-22 2006-08-21 Новое применение производного азабициклогексана EA016084B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517193.9A GB0517193D0 (en) 2005-08-22 2005-08-22 Novel use
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives

Publications (2)

Publication Number Publication Date
EA200800655A1 true EA200800655A1 (ru) 2008-08-29
EA016084B1 EA016084B1 (ru) 2012-02-28

Family

ID=35098098

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800655A EA016084B1 (ru) 2005-08-22 2006-08-21 Новое применение производного азабициклогексана

Country Status (20)

Country Link
US (2) US20090036461A1 (ru)
EP (1) EP1917013B1 (ru)
JP (1) JP5166267B2 (ru)
KR (1) KR101363090B1 (ru)
CN (1) CN101291669B (ru)
AT (1) ATE500826T1 (ru)
AU (1) AU2006284077B2 (ru)
BR (1) BRPI0614929A2 (ru)
CA (1) CA2620090A1 (ru)
CR (1) CR9807A (ru)
DE (1) DE602006020589D1 (ru)
EA (1) EA016084B1 (ru)
ES (1) ES2361933T3 (ru)
GB (1) GB0517193D0 (ru)
IL (1) IL189435A0 (ru)
MA (1) MA29774B1 (ru)
MX (1) MX2008002564A (ru)
NO (1) NO20081314L (ru)
WO (1) WO2007022980A1 (ru)
ZA (1) ZA200801352B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047890A1 (es) * 2004-02-23 2006-03-01 Glaxo Group Ltd Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
EP2007751B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
RU2012102094A (ru) * 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9314600B2 (en) 2012-04-15 2016-04-19 Bioconnect Systems, Inc. Delivery system for implantable flow connector
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
AR047890A1 (es) * 2004-02-23 2006-03-01 Glaxo Group Ltd Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
SE526837C2 (sv) 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
JP5049134B2 (ja) * 2004-12-02 2012-10-17 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適なトリアゾール化合物
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
MX2008012875A (es) * 2006-04-03 2008-10-13 Glaxo Group Ltd Derivados de azabiciclo [3.1.0] hexilo como moduladores de los receptores d3 de la dopamina.
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EA016084B1 (ru) 2012-02-28
BRPI0614929A2 (pt) 2011-04-19
CR9807A (es) 2008-07-29
DE602006020589D1 (de) 2011-04-21
NO20081314L (no) 2008-03-17
EP1917013B1 (en) 2011-03-09
KR20080040022A (ko) 2008-05-07
ATE500826T1 (de) 2011-03-15
GB0517193D0 (en) 2005-09-28
EP1917013A1 (en) 2008-05-07
AU2006284077A1 (en) 2007-03-01
WO2007022980A1 (en) 2007-03-01
JP2009506989A (ja) 2009-02-19
CN101291669B (zh) 2012-09-26
CN101291669A (zh) 2008-10-22
ES2361933T3 (es) 2011-06-24
JP5166267B2 (ja) 2013-03-21
MX2008002564A (es) 2008-03-18
IL189435A0 (en) 2008-08-07
CA2620090A1 (en) 2007-03-01
AU2006284077B2 (en) 2012-05-17
MA29774B1 (fr) 2008-09-01
US20120196910A1 (en) 2012-08-02
ZA200801352B (en) 2009-01-28
US20090036461A1 (en) 2009-02-05
KR101363090B1 (ko) 2014-02-13

Similar Documents

Publication Publication Date Title
EA200800655A1 (ru) Производные азабициклогексана
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
GEP20094727B (en) Oxyindole derivatives as 5ht4 receptor agonists
EA200700099A1 (ru) Производные пиридина
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
GB0612423D0 (en) Therapeutic agents
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA200970067A1 (ru) Агонисты ep2
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
EA201290229A1 (ru) Производные спиролактама и их применение
EA200800151A1 (ru) Производные хинолина в качестве антибактериальных агентов
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
IL191928A0 (en) Triazoloanilinopyrimidine derivatives for use as antiviral agents
MX2010001303A (es) Compuestos terapeuticos.
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU